Objective: To optimize image-guided prostate biopsy by minimizing the target error with trocar-sharpened needle tips instead of beveled needles, which constantly deviate away from the bevel. Materials and Methods: We performed stereotactic biopsies on two prostate phantoms, which incorporate three randomly placed TRUS-visible lesions. Four stereotactic biopsies per lesion were taken under live-ultrasound guidance through a template: two biopsies with conventional beveled needles and two biopsies with novel trocar-sharpened needles. The procedural targeting error (PTE) between the virtually planned biopsy trajectory and the manually registered 3D needle position of every single biopsy core taken was calculated. Results: The absolute overall targeting error using the novel needle-tip design was 0.13 mm (SD: ± 0.15 mm) with the highest PTE in the sagittal plane (0.18 ± 0.16 mm), followed by the coronal (0.13 ± 0.17 mm) and axial (0.09 ± 0.05 mm) planes. Comparing the PTE of the novel trocar-shaped needles with conventional beveled needles, there was a statistically significant difference in the axial plane [p (overall) = 0.47, p(axial) = 0.03]. Conclusion: The targeting error of stereotactic biopsies using trocar-sharpened needles is significantly lower than the targeting error of classical beveled needles. Thus, trocar-tip configurations improve the accuracy of computer-assisted biopsies and allow precise assessment of suspicious lesions in the prostate and in other organs accessible to image-guided biopsy.

Keywords:
Trocar-tip needle, Beveled needle, Image-guided biopsy, Prostate, Target deviation
1.
Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, et al: Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol 2012;187:1247-1252.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3.
Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, et al: Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 2012;61:370-377.
4.
Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al: Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962-977.
5.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
6.
Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, et al: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183:520-527.
7.
Pondman KM, Fütterer JJ, ten Haken B, Schultze Kool LJ, Witjes JA, Hambrock T, et al: MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 2008;54:517-527.
8.
Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al: Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62:902-909.
9.
Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, Irie T, et al: Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 2010;17:855-860.
10.
Cooperberg MR, Carroll PR, Klotz L: Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669-3676.
11.
Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, et al: Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 2008;101:841-845.
12.
Turkbey B, Xu S, Kruecker J, Locklin J, Pang Y, Bernardo M, et al: Documenting the location of prostate biopsies with image fusion. BJU Int 2011;107:53-57.
13.
Ukimura O, Hirahara N, Fujihara A, Yamada T, Iwata T, Kamoi K, et al: Technique for a hybrid system of real-time transrectal ultrasound with preoperative magnetic resonance imaging in the guidance of targeted prostate biopsy. Int J Urol 2010;17:890-893.
14.
Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, et al: Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008;13:255-264.
15.
Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al: Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63:125-140.
16.
Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al: Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011;186:1818-1824.
17.
Roethke MC, Lichy MP, Kniess M, Werner MK, Claussen CD, Stenzl A, et al: Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol 2012, E-pub ahead of print.
18.
Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, et al: MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30:213-218.
19.
Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, et al: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-125.
20.
Ahmed HU, Emberton M, Kepner G, Kepner J: A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol 2012;9:227-231.
21.
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, et al: The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
22.
Panteliou SD, Tzortzis V, Anagnostopoulos GT, Sunaric MM, Sarris J, Hatzimouratidis K, et al: Development of a new optical device and its feasibility in prostate cancer detection. Urol Int 2012;89:290-295.
23.
Pinto F, Totaro A, Palermo G, Calarco A, Sacco E, D'Addessi A, et al: Imaging in prostate cancer staging: present role and future perspectives. Urol Int 2012;88:125-136.
24.
Colleselli D, Hennenlotter J, Schilling D, Krueger SA, Roethke M, Lichy MP, et al: Impact of clinical parameters on the diagnostic accuracy of endorectal coil MRI for the detection of prostate cancer. Urol Int 2011;86:393-398.
25.
Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, et al: MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50:738-748, discussion 748-749.
26.
Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, et al: A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011;186:2214-2220.
27.
Kuru TH, Roethke M, Popeneciu V, Teber D, Pahernik S, Zogal P, et al: Phantom study of a novel stereotactic prostate biopsy system integrating preinterventional magnetic resonance imaging and live ultrasonography fusion. J Endourol 2012;26:807-813.
28.
Kopacz DJ, Allen HW: Comparison of needle deviation during regional anesthetic techniques in a laboratory model. Anesth Analg 1995;81:630-633.
29.
Fütterer JJ, Barentsz JO: MRI-guided and robotic-assisted prostate biopsy. Curr Opin Urol 2012;22:316-319.
30.
Muntener M, Patriciu A, Petrisor D, Schär M, Ursu D, Song DY, et al: Transperineal prostate intervention: robot for fully automated MR imaging - system description and proof of principle in a canine model. Radiology 2008;247:543-549.
31.
Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, Betrouni N, et al: Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. Urology 2011;78:1356-1362.
32.
Obek C, Doğanca T, Erdal S, Erdoğan S, Durak H: Core length in prostate biopsy: size matters. J Urol 2012;187:2051-2055.
33.
Ploussard G, La Taille de A, Terry S, Allory Y, Ouzaïd I, Vacherot F, et al: Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urol Oncol 2012, E-pub ahead of print.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.